Production (Stage)
Citius Oncology, Inc.
CTOR
$1.44
-$0.03-2.04%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -15.57% | -4.51% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 16.83% | -4.11% | |||
| Operating Income | -16.83% | 4.11% | |||
| Income Before Tax | -16.83% | 4.11% | |||
| Income Tax Expenses | 0.00% | 83.47% | |||
| Earnings from Continuing Operations | -16.16% | 2.26% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -16.16% | 2.26% | |||
| EBIT | -16.83% | 4.11% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -16.11% | 4.71% | |||
| Normalized Basic EPS | -16.82% | 6.52% | |||
| EPS Diluted | -16.11% | 4.71% | |||
| Normalized Diluted EPS | -16.82% | 6.52% | |||
| Average Basic Shares Outstanding | 0.00% | 2.64% | |||
| Average Diluted Shares Outstanding | 0.00% | 2.64% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||